Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI130 in advanced solid tumors
NCT05923008Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IBI-130 in solid tumor, triple-negative breast cancer (TNBC), sponsored by Innovent Biologics. Started Nov 2023; status: recruiting.
02
Drugs
IBI-130
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05923008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923008.